Home > Dermatology > PFGC 2021 > Comorbidity in Psoriasis > Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation

Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation

Presented By
Dr Niamh Kearney, St. Vincent’s University Hospital, Ireland
Conference
PFGC 2021
A cohort study revealed that the novel biomarker systemic immune-inflammation index (SII), associated with a worse prognosis in different disease entities, was markedly elevated in psoriasis patients with concomitant cardiovascular comorbidity. There was a weak but significant correlation with the Psoriasis Area and Severity Index (PASI) but no correlation with smoking status. “The systemic immune inflammation (SII) index is a simple calculation of neutrophils multiplied by platelets divided by lymphocytes,” Dr Niamh Kearney (St. Vincent’s University Hospital, Ireland) explained [1]. The SII has proven to be a promising prognostic indicator in various cancers, COVID-19 and other diseases. In patients with coronary artery disease, this index provides a better prediction of major cardiovascular events than traditional risk factors [2]. Severe psoriasis is associated with a distinct risk elevation for cardiovascular events and death. With their retrospective ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on